Status:
COMPLETED
Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
Lead Sponsor:
Mayo Clinic
Conditions:
Cirrhosis
Portal Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Octreotide is used to control variceal bleeding. However, octreotide has to be given through the vein and is effective for less than two hours. In this study the investigators determined whether a lo...
Eligibility Criteria
Inclusion
- Cirrhosis documented by biopsy, or suggested by characteristic features on abdominal imaging (nodular appearance, irregular contour) along with impaired synthetic liver function and thrombocytopenia and Child Turcotte Pugh Class A or B.
- presence of small esophageal varices, defined as varices \< 5 mm in diameter, without red signs documented on endoscopy within 3 months of enrollment
- age ≥ 18 years
Exclusion
- pregnant, lactating or of child-bearing potential and not practicing acceptable method of birth control
- allergic to sandostatin
- high risk varices on endoscopy carried out within 3 months of assessment (large varices or red signs)
- Child Turcotte Pugh Class C cirrhosis
- hepatocellular carcinoma
- evidence of ongoing alcohol or illicit drug abuse within 6 months of the study
- serum creatinine greater than 2 mg/dL
- platelet count below 50,000 per microliter
- prothrombin time 4 seconds or more greater than control
- human immunodeficiency virus (HIV) positive
- symptomatic gallstones
- previous history of upper gastrointestinal bleeding in the past 3 months, defined as hematemesis and/or melena
- previous history of variceal bleeding
- history of congestive heart failure , unstable angina, sustained ventricular tachycardia, or ventricular fibrillation
- use of any investigational drug within 1 month prior to screening and
- current use of beta blockers or long-acting nitrates, any other drug therapy known to have an influence on portal pressure (diuretics were allowed provided patients were on a stable dose for at least 30 days).
Key Trial Info
Start Date :
June 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2000
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01188733
Start Date
June 1 1998
End Date
December 1 2000
Last Update
August 25 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.